DOCSLIB.ORG

Chapter 6 |Management of Morbidity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chapter 6 |Management of Morbidity NATIONAL MEDICAL CARE STATISTICS 2010 CHAPTER 6 | MANAGEMENT OF MORBIDITY 6.1 PRESCRIBED MEDICATION Anatomical Therapeutic Chemical (ATC) Classification System The drugs prescribed in a primary care setting were coded according to the ATC classification, which categorises the active ingredients into different groups according to the body system or organ on which they exert their effects as well as their chemical, pharmacological and therapeutic properties. According to the code, each drug is classified at five different levels. first Level is the main group, which consists of mostly organs or body systems. Each of the 14 main groups in Level 1 are divided at 2nd Level according to their pharmacological and therapeutic effects, which are further subdivided at 3rd and 4th levels based on their chemical, pharmacological and therapeutic properties. The 5th Level of the code indicates the chemical substance1. An example of ATC classification for amlodipine is shown below. The full ATC code for plain amlodipine products is thus C08CA01. LEVELS ATC CODE ATC DESCRIPTION 1 C Cardiovascular system 2 C08 Calcium channel blockers 3 C08C Selective calcium channel blockers with mainly vascular effects 4 C08C A Dihydropyridine derivatives 5 C08C A01 Amlodipine Types of Drugs Prescribed A total of 54,532 drugs were prescribed in NMCS 2010, out of which 54,204 drugs (99.4%) were coded according to the ATC classification. The remaining 328 drugs could not be coded due to illegible writing or spelling errors. In this report, data is being presented according to the main groups (ATC Level 1 – Table 6.1) and main therapeutic groups (ATC Level 2 – Table 6.2) followed by a list of Top 100 most prescribed medications, in descending order (Table 6.3). Overall, respiratory system drugs were the highest prescribed (R – 24.1%), with an average of 59.8 encounters (95%CI 59.7 – 59.9) being given a drug from this group in every 100 encounters. This is followed by drugs for alimentary tract and metabolism (A – 18.5%) and drugs for nervous system (N – 14.2%) (Table 6.1). Antihistamines for systemic use (R06 – 13.4%) were the most frequently prescribed main therapeutic group (ATC Level 2), followed by analgesics (N02 – 12.0%), antibacterials for systemic use (J01 – 11.1%), anti-inflammatory and antirheumatic products (M01 – 9.3%) and cough and cold preparations (R05 – 4.3%). All 78 ATC Level 2 Codes identified in NMCS 2010 are listed in Table 6.2. Among all the 54,204 coded drugs, paracetamol (11.1%) was the most prescribed drug, far outnumbering diphenhydramine combination products (4.3%), chlorphenamine (or chlorpheniramine – 3.8%), mefenamic acid (3.4%) and amoxicillin (3.3%) (Table 6.3). Reference 1. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2011. Oslo, 2010. Management of Morbidity 6 17 NATIONAL MEDICAL CARE STATISTICS 2010 Table 6.1 Distribution of prescribed medications by ATC Level 1 in NMCS 2010, in descending order PROPortion 95 % CI RATE PER 100 ATC OF PRESCRIBED NO ATC LEVEL 1 DESCRIPTION NUMBER* ENCOUNTER L1 MEDICATIONS (%)** (N = 21,868) LOWER UPPER (N = 54,204) 1 R Respiratory system 13,068 24.11 59.76 59.66 59.86 2 A Alimentary tract and metabolism 10,039 18.52 45.91 45.82 46.00 3 N Nervous system 7,710 14.22 35.26 35.19 35.34 4 M Musculo-skeletal system 7,239 13.36 33.10 32.02 33.18 5 J Antiinfectives for systemic use 6,657 12.28 30.44 30.37 30.51 6 C Cardiovascular system 3,340 6.16 15.27 15.22 15.33 7 D Dermatologicals 2,478 4.57 11.33 11.29 11.38 Systemic hormonal preparations, 8 H 1,239 2.29 5.67 5.63 5.70 excl. sex hormones and insulins 9 B Blood and blood forming organs 848 1.56 3.88 3.85 3.90 10 S Sensory organs 781 1.44 3.57 3.55 3.60 Genitourinary system and sex 11 G 478 0.88 2.19 2.17 2.21 hormones Antiparasitic products, 12 P 317 0.58 1.45 1.43 1.47 insecticides and repellents 13 V Various 8 0.01 0.04 0.03 0.04 Antineoplastic and 14 L 2 0.00 0.01 0.01 0.01 immunomodulating agents TOTAL CODED DRUGS 54,204 100.00 - - - * frequency of total coded drugs ** calculated based on total coded drugs (n = 54,204) 18 NATIONAL MEDICAL CARE STATISTICS 2010 Table 6.2: Distribution of prescribed medications by ATC level 2 in NMCS 2010, in descending order PROPortion 95 % CI RATE PER 100 OF PRESCRIBED NO ATC L2 ATC LEVEL 2 DESCRIPTIONS NUMBER* ENCOUNTER MEDICATIONS (%)** (N = 21,868) LOWER UPPER (N = 54,204) 1 R06 Antihistamines for systemic use 7,191 13.35 32.88 32.80 32.96 2 N02 Analgesics 6,455 11.98 29.52 29.45 29.59 3 J01 Antibacterials for systemic use 5,992 11.12 27.40 27.33 27.47 Antiinflammatory and 4 M01 5,000 9.28 22.86 22.80 22.93 antirheumatic products 5 R05 Cough and cold preparations 2,316 4.30 10.59 10.55 10.63 6 A02 Drugs for acid related disorders 2,315 4.30 10.59 10.54 10.63 Drugs for functional 7 A03 2,144 3.98 9.80 9.76 9.85 gastrointestinal disorders Antidiarrheals, intestinal 8 A07 antiinflammatory / 1,764 3.27 8.07 8.03 8.10 antiinfective agents 9 R01 Nasal preparations 1,636 3.04 7.48 7.45 7.52 10 A11 Vitamins 1,560 2.90 7.13 7.10 7.17 11 H02 Corticosteroids for systemic use 1,194 2.22 5.46 5.43 5.49 12 A10 Drugs used in diabetes 1,188 2.21 5.43 5.40 5.46 Drugs for obstructive airway 13 R03 1,104 2.05 5.05 5.02 5.08 diseases Corticosteroids, dermatological 14 D07 835 1.55 3.82 3.79 3.84 preparations 15 R02 Throat preparations1 821 1.52 3.75 3.73 3.78 Other drugs for disorders of the 16 M09 775 1.44 3.54 3.52 3.57 musculo-skeletal system2 17 M03 Muscle relaxants 728 1.35 3.33 3.30 3.35 18 C07 Beta blocking agents 718 1.33 3.28 3.26 3.31 19 C10 Lipid modifying agents 681 1.26 3.11 3.09 3.14 20 N05 Psycholeptics 663 1.23 3.03 3.01 3.05 21 C08 Calcium channel blockers 650 1.21 2.97 2.95 3.00 Agents acting on the 22 C09 633 1.17 2.89 2.87 2.92 renin-angiotensin system Topical products for 23 M02 596 1.11 2.73 2.70 2.75 joint and muscular pain 24 B03 Antianemic preparations3 573 1.06 2.62 2.60 2.64 Antifungals for 25 D01 499 0.93 2.28 2.26 2.30 dermatological use 26 S01 Ophthalmologicals 492 0.91 2.25 2.23 2.27 27 A12 Mineral supplements 427 0.79 1.95 1.93 1.97 Management of Morbidity 4 28 N07 Other nervous system drugs 416 0.77 1.90 1.88 1.92 6 19 NATIONAL MEDICAL CARE STATISTICS 2010 Table 6.2: Distribution of prescribed medications by ATC level 2 in NMCS 2010, in descending order (CONT) PROPortion 95 % CI RATE PER 100 OF PRESCRIBED NO ATC L2 ATC LEVEL 2 DESCRIPTIONS NUMBER* ENCOUNTER MEDICATIONS (%)** (N = 21,868) LOWER UPPER (N = 54,204) 29 C03 Diuretics 404 0.75 1.85 1.83 1.87 Antibiotics and chemotherapeutics 30 D06 371 0.69 1.70 1.68 1.71 for dermatological use 31 J07 Vaccines 326 0.61 1.49 1.47 1.51 Antipruritics, incl. antihistamines, 32 D04 312 0.58 1.43 1.41 1.44 anesthetics, etc. Sex hormones and modulators of 33 G03 268 0.50 1.23 1.21 1.24 the genital system 34 A01 Stomatological preparations 264 0.49 1.21 1.19 1.22 35 B01 Antithrombotic agents 237 0.44 1.08 1.07 1.10 36 A06 Laxatives 207 0.38 0.95 0.93 0.96 37 P01 Antiprotozoals 204 0.38 0.93 0.92 0.95 38 D02 Emollients and protectives 190 0.35 0.87 0.86 0.88 Ophthalmological and 39 S03 170 0.32 0.78 0.77 0.79 otological preparations 40 J02 Antimycotics for systemic use 168 0.31 0.77 0.76 0.78 Antiseptics and disinfectants, 41 D08 161 0.30 0.74 0.72 0.75 topical 42 G04 Urologicals 160 0.30 0.73 0.72 0.74 43 M04 Antigout preparations 133 0.25 0.61 0.60 0.62 44 J05 Antivirals for systemic use 127 0.24 0.58 0.57 0.59 45 S02 Otologicals 119 0.22 0.54 0.53 0.55 46 C05 Vasoprotectives 115 0.21 0.53 0.52 0.54 47 N06 Psychoanaleptics 106 0.20 0.48 0.48 0.49 48 C01 Cardiac therapy5 78 0.14 0.36 0.35 0.36 Ectoparasiticides, incl. scabicides, 49 P03 61 0.11 0.28 0.27 0.29 insecticides and repellents 50 C02 Antihypertensives 60 0.11 0.27 0.27 0.28 51 A13 Tonics 55 0.10 0.25 0.24 0.26 52 P02 Anthelmintics 52 0.10 0.24 0.23 0.24 Gynecological antiinfectives 53 G01 48 0.09 0.22 0.21 0.23 and antiseptics Antiobesity preparations, excl.
Load more

Recommended publications
  • Appendix a Common Abbreviations Used in Medication
    UNIVERSITY OF AMSTERDAM MASTERS THESIS Impact of Medication Grouping on Fall Risk Prediction in Elders: A Retrospective Analysis of MIMIC-III Critical Care Database Student: SRP Mentor: Noman Dormosh Dr. Martijn C. Schut Student No. 11412682 – SRP Tutor: Prof. dr. Ameen Abu-Hanna SRP Address: Amsterdam University Medical Center - Location AMC Department Medical Informatics Meibergdreef 9, 1105 AZ Amsterdam Practice teaching period: November 2018 - June 2019 A thesis submitted in fulfillment of the requirements for the degree of Master of Medical Informatics iii Abstract Background: Falls are the leading cause of injury in elderly patients. Risk factors for falls in- cluding among others history of falls, old age, and female gender. Research studies have also linked certain medications with an increased risk of fall in what is called fall-risk-increasing drugs (FRIDs), such as psychotropics and cardiovascular drugs. However, there is a lack of consistency in the definitions of FRIDs between the studies and many studies did not use any systematic classification for medications. Objective: The aim of this study was to investigate the effect of grouping medications at different levels of granularity of a medication classification system on the performance of fall risk prediction models. Methods: This is a retrospective analysis of the MIMIC-III cohort database. We created seven prediction models including demographic, comorbidity and medication variables. Medica- tions were grouped using the anatomical therapeutic chemical classification system (ATC) starting from the most specific scope of medications and moving up to the more generic groups: one model used individual medications (ATC level 5), four models used medication grouping at levels one, two, three and four of the ATC and one model did not include med- ications.
    [Show full text]
  • Summary of Product Characteristics
    Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT MAXITROL ophthalmic ointment 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Ophthalmic ointment: 1 g ointment contains 1 mg dexamethasone, 3,500 I.U. neomycin sulphate (as base) and 6,000 I.U.polymyxin B sulphate. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Ophthalmic ointment White to very pale yellow homogeneous translucent ointment 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Maxitrol ophthalmic ointment is indicated for the treatment of eye infections which are responsive to steroids, when an antibiotic is also needed. 4.2 Posology and method of administration Children and Adults (including the Elderly) Apply a small amount (1-1.5 cm) in the conjunctival sac 3 to 4 times daily, or use as a supplement to the eye drops at bedtime. After application of the ointment, look downward for a moment before closing the eyes. Method of administration: For ocular use. To prevent contamination of the tube tip and ointment, care must be taken not to touch the eyelids, surrounding areas, or other surfaces with the tube tip. Keep the tube tightly closed when not in use. 4.3 Contraindications • Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. • Herpes simplex keratitis. • Vaccinia, varicella, and other viral infection of cornea or conjunctiva. • Fungal diseases of ocular structures. • Mycobacterial ocular infections. 4.4 Special warnings and precautions for use - For topical ophthalmic use only. Not for injection or ingestion. - As with all antibacterial preparation prolonged use may lead to overgrowth of non- susceptible bacterial strains or fungi.
    [Show full text]
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • How to Fortify Beverages with Calcium by Dr
    Ingredients How to Fortify Beverages With Calcium by Dr. Gerhard Gerstner Along with current developments of the overall functional foods market, the use of minerals and especially calcium salts is expected to exhibit strong growth rates. In contrary to other functional ingredients, calcium is widely known as being beneficial for human health and there is no need to explain its nutritional ad- vantages to the customer. According to Leatherhead International, future trends include growing consumer concern regarding osteoporosis and bone health, leading to increased sales of calcium salts. The con- observation is seen as being one of tinuous market growth drives mineral the main factors causing osteo- Common calium sources salt suppliers to offer not only one porosis 2 .As a consequence, national for beverage fortification product but rather a range of different authorities all over the world have calcium salts and granulations to be recently reconsidered recommend- Table 1 shows a typical range of able to tune them to industrial cus- ations in order to take remedial calcium fortified beverages which tomers’ applications. This article measures against calcium deficiency have been seen in European and US discusses important nutritional, and accordingly, to reduce the risk of supermarkets recently. Practically technological as well as economical osteoporosis. In this respect, the US every type of beverage such as aspects of calcium in beverages with National Institute of Health (NIH) has mineral water, soy milk, energy drink, a focus on our company’s products increased the amounts of optimal nectar or juice does have a fortified Tricalcium Citrate, Calcium Gluconate daily calcium intake and defined product line already.
    [Show full text]
  • Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis
    Journal of Allergy Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis Guest Editors: Ralph Mösges, Carlos E. Baena-Cagnani, and Desiderio Passali Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis Journal of Allergy Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis Guest Editors: Ralph Mosges,¨ Carlos E. Baena-Cagnani, and Desiderio Passali Copyright © 2014 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “Journal of Allergy.” All articles are open access articles distributed under the Creative Commons At- tribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board William E. Berger, USA Alan P. Knutsen, USA Fabienne Ranc, France Kurt Blaser, Switzerland Marek L. Kowalski, Poland Anuradha Ray, USA Eugene R. Bleecker, USA Ting Fan Leung, Hong Kong Harald Renz, Germany JandeMonchy,TheNetherlands Clare M Lloyd, UK Nima Rezaei, Iran Frank Hoebers, The Netherlands Redwan Moqbel, Canada Robert P. Schleimer, USA StephenT.Holgate,UK Desiderio Passali, Italy Massimo Triggiani, Italy Sebastian L. Johnston, UK Stephen P. Peters, USA Hugo Van Bever, Singapore Young J. Juhn, USA David G. Proud, Canada Garry Walsh, United Kingdom Contents Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis,RalphMosges,¨ Carlos E. Baena-Cagnani, and Desiderio Passali Volume 2014, Article ID 416236, 2 pages Clinical Efficacy of a Spray Containing Hyaluronic Acid and Dexpanthenol after Surgery in the Nasal Cavity (Septoplasty, Simple Ethmoid Sinus Surgery, and Turbinate Surgery), Ina Gouteva, Kija Shah-Hosseini, and Peter Meiser Volume 2014, Article ID 635490, 10 pages The Effectiveness of Acupuncture Compared to Loratadine in Patients Allergic to House Dust ,Mites Bettina Hauswald, Christina Dill, Jurgen¨ Boxberger, Eberhard Kuhlisch, Thomas Zahnert, and Yury M.
    [Show full text]
  • More Than Expectorant: New Scientific Data on Ambroxol in the Context of the Treatment of Bronchopulmonary Diseases
    Mini Review iMedPub Journals Journal of Intensive and Critical Care 2017 www.imedpub.com ISSN 2471-8505 Vol. 3 No. 3: 37 DOI: 10.21767/2471-8505.100096 More than Expectorant: New Scientific Data Manuel Plomer1* and 2 on Ambroxol in the Context of the Treatment Justus de Zeeuw of Bronchopulmonary Diseases 1 Medical Affairs CHC Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, D-65926, Frankfurt am Main, Deutschland, German Abstract 2 Medical Specialist for Internal Medicine, Pneumology and Sleep Medicine, Background:Ambroxol has been established for decades in the treatment of Cologne, Germany, German acute and chronic respiratory diseases. A reassessment of the benefit-risk was conducted recently. Objective: What new scientific data, relevant for the treatment of *Corresponding author: bronchopulmonary diseases, were published in the last decade? Dr. Manuel Plomer Method: Systematic literature search via http://www.pubmed.gov with the search term “ambroxol”, covering the publication period from 2006 to 2015. Non- [email protected] relevant publications were excluded manually. Medical Manager, Medical Affairs CHC Results: 64 relevant publications could be identified covering both, clinical and Germany, Sanofi-Aventis Deutschland GmbH, preclinical research. Industriepark Höchst, D-65926 Frankfurt am Conclusion: The traditional indication of ambroxol as an expectorant is confirmed Main, Germany. but new results revealed a better understanding of the various mechanisms of action of ambroxol and the benefits for special patient populations. The Tel: 49 69 305 36803 available data suggest the use of ambroxol as an adjuvant in anti-infective therapy, particularly in case of infections with biofilm-producing pathogens. Lung- protective properties are discussed in both infants and severely ill adult patients.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • European Journal of Scientific Exploration Vol 3 №2 2020
    EUROPEAN JOURNAL OF SCIENTIFIC EXPLORATION VOL 3 №2 2020 Determination of Oligomer Content in Benzonatate Drug Substance by HPLC Lakshmi Narasimha Rao Katakam 1 Santhosh Kumar Ettaboina 2 Thirupathi Dongala 2 1Saptalis Pharmaceuticals LLC, New York, USA 2Aurex Pharmaceuticals Inc, East Windsor, USA Abstract. A reverse-phase liquid chromatographic method has developed and validated to determine oligomer content in Benzonatate Drug substances. This method has a separation of relatively few monomer units, which constitutes an oligomer with a minimum adequate chromatographic resolution of 1.0 from each of the subject component peaks. The separation achieved using Phenomenex Luna C18 (250 X 4.6 mm) 5 µm column at a flow rate of 1.0 ml/min with an isocratic elution method. The mobile phase consisting of 0.25% Ammonium formate buffer and methanol in the ratio 350:650 (v/v), respectively. The Oligomer compounds detection carried out at UV 310 nm, and the LC method validated as per the current ICH Q2 guidelines. The method is effectively validated and proved to be precise, specific, linear, robust, and rugged to quantitate oligomer content in Benzonatate drug substance. Key words: benzonatate (BNZ), oligomers, HPLC, method validation. Introduction Benzonatate (BNZ) is an oral antitussive drug used to relieve and suppress cough in patients older than ten years of age (Oligomer Wikipedia, 2020). Currently, BNZ is the only non-narcotic antitussive available as a prescription drug. The chemical structure resembles that of the anesthetic agents in the para-amino-benzoic acid class (such as procaine and tetracaine), BNZ exhibits anesthetic or numbing action. BNZ also inhibits the transmission of impulses of the cough reflex in the medulla's vagal nuclei (Tessalon, 2020).
    [Show full text]
  • 1 Brief Report: the Virucidal Efficacy of Oral Rinse Components Against SARS-Cov-2 in Vitro Evelina Statkute1†, Anzelika Rubin
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Brief Report: The Virucidal Efficacy of Oral Rinse Components Against SARS-CoV-2 In Vitro Evelina Statkute1†, Anzelika Rubina1†, Valerie B O’Donnell1, David W. Thomas2† Richard J. Stanton1† 1Systems Immunity University Research Institute, Division of Infection & Immunity, School of Medicine, Heath Park, Cardiff, CF14 4XN 2Advanced Therapies Group, School of Dentistry, Cardiff University, Heath Park, Cardiff CF14 4XY, UK †These authors contributed equally * Correspondence: [email protected], [email protected] Running title: Virucidal Activity of Mouthwashes Keywords: SARS-CoV2, mouthwash, lipid, envelope Disclosure: Venture Life Group plc provided information on mouthwash formulations employed in the study, but had no role in funding, planning, execution, analysis or writing of this study. A separate study funded to Cardiff University by Venture Life Group is assessing in vivo efficacy of CPC in patients with COVID19. The investigators declare no direct conflicts exist. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license.
    [Show full text]
  • Appendix on Tariff Elimination Schedule for Mercosur
    Trade part of the EU-Mercosur Association Agreement Without Prejudice Disclaimer: In view of the Commission's transparency policy, the Commission is publishing the texts of the Trade Part of the Agreement following the agreement in principle announced on 28 June 2019. The texts are published for information purposes only and may undergo further modifications including as a result of the process of legal revision. However, in view of the growing public interest in the negotiations, the texts are published at this stage of the negotiations for information purposes. These texts are without prejudice to the final outcome of the agreement between the EU and Mercosur. The texts will be final upon signature. The agreement will become binding on the Parties under international law only after completion by each Party of its internal legal procedures necessary for the entry into force of the Agreement (or its provisional application). AR applied BR applied PY applied UY applied Mercosur Final NCM Description Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 01022911 Other bovine animals for breeding,pregnant or lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 01023911 Other buffalo for breeding, ex.
    [Show full text]
  • Potassium-Magnesium Citrate Is an Effective Prophylaxis Against Recurrent Calcium Oxalate Nephrolithiasis
    0022-5347/97/1586-2069$03.00/0 JOURNAL OF UROLOGY Vol. 158,2069-2073, December 1997 Copyright Q 1997 by AMERICANUROLOGICAL ASS~CIATION, INC. Printed in U.S.A. POTASSIUM-MAGNESIUM CITRATE IS AN EFFECTIVE PROPHYLAXIS AGAINST RECURRENT CALCIUM OXALATE NEPHROLITHIASIS BRUCE ETTINGER,* CHARLES Y. C. PAK, JOHN T. CITRON, CARL THOMAS, BEVERLEY ADAMS-HIJET AND ARLINE VANGESSEL From the Diuision of Research, Kaiser Permanente Medical Care Program, Oakland, California, the Department of Mineral Metabolism, Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, Department of Medicine, Kaiser Permanente Medical Center, Walnut Creek, California, Department of Urology, Kaiser Permanente Medical Center, San Francisco, California, and Kaiser Foundation Research Institute, Kaiser Foundation Hospitals, Oakland, California ABSTRACT Purpose: We examined the efficacy of potassium-magnesium citrate in preventing recurrent calcium oxalate kidney calculi. Materials and Methods: We conducted a prospective double-blind study of 64 patients who were randomly assigned to receive placebo or potassium-magnesium citrate (42 mEq. potassium, 21 mEq. magnesium, and 63 mEq. citrate) daily for up to 3 years. Results. New calculi formed in 63.6%of subjects receiving placebo and in 12.9%of subjects receiving potassium-magnesiumcitrate. When compared with placebo, the relative risk of treat- ment failure for potassium-magnesium citrate was 0.16 (95%confidence interval 0.05 to 0.46). potassium-magnesium citrate had a statistically significant effect (relative risk 0.10,95%confi- dence interval 0.03 to 0.36) even after adjustment for possible confounders, including age, pretreatment calculous event rate and urinary biochemical abnormalities.
    [Show full text]
  • Electro-Activation of Potassium Acetate, Potassium Citrate and Calcium
    Liato et al. SpringerPlus (2016) 5:1760 DOI 10.1186/s40064-016-3453-1 RESEARCH Open Access Electro‑activation of potassium acetate, potassium citrate and calcium lactate: impact on solution acidity, Redox potential, vibrational properties of Raman spectra and antibacterial activity on E. coli O157:H7 at ambient temperature Viacheslav Liato1,2, Steve Labrie1,3 and Mohammed Aïder1,2,4* *Correspondence: [email protected] Abstract 1 Institute of Nutrition and Functional Foods (INAF), Aims: To study the electro-activation of potassium acetate, potassium citrate and Université Laval, Quebec, QC calcium lactate aqueous solutions and to evaluate their antimicrobial effect against E. G1V 0A6, Canada coli O157:H7 at ambient temperature. Full list of author information is available at the end of the Methods and results: Potassium acetate, potassium citrate and calcium lactate aque- article ous solutions were electrically excited in the anodic compartment of a four sectional electro-activation reactor. Different properties of the electro-activated solutions were measured such as: solutions acidity (pH and titratable), Redox potential and vibrational properties by Raman spectroscopy. Moreover, the antimicrobial activity of these solu- tions was evaluated against E. coli O157:H7. The results showed a pH decrease from 7.07 0.08, 7.53 0.12 and 6.18 0.1 down to 2.82 0.1, 2.13 0.09 and 2.26 0.15, after ±180 min of electro-activation± ± of potassium acetate,± potassium± citrate and calcium± lactate solution, respectively. These solutions were characterized by high oxidative ORP of 1076 12, 958 11 and 820 14 mV, respectively.
    [Show full text]